✦ LIBER ✦

Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis

✍ Scribed by Parikh, Sameer A.; Kantarjian, Hagop M.; Richie, Mary Ann; Cortes, Jorge E.; Verstovsek, Srdan

Book ID: 120469404
Publisher: Informa plc
Year: 2009
Tongue: English
Weight: 189 KB
Volume: 51
Category: Article
ISSN: 1042-8194
DOI: 10.3109/10428190903486220

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I study of the oral mammalian targ

Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma

✍ Kensei Tobinai; Michinori Ogura; Dai Maruyama; Toshiki Uchida; Naokuni Uike; Ils 📂 Article 📅 2010 🏛 Carden Jennings Publishing 🌐 English ⚖ 345 KB

A pilot trial of the mTOR (mammalian tar

A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL

✍ Thomas Decker; Michael Sandherr; Katharina Goetze; Madlen Oelsner; Ingo Ringshau 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 151 KB

O-99 The mTOR (mammalian target of rapam

O-99 The mTOR (mammalian target of rapamycin) inhibitor RAD001 (Everolimus) is safe and reduces proliferation in postmenopausal women with breast cancer

✍ E.J. Macaskill; J.M.S. Bartlett; L. Renshaw; D. Faratian; S. White; F.M. Campbel 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 43 KB

A phase 2 study of the oral mammalian ta

A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma

✍ Brian M. Slomovitz; Karen H. Lu; Taren Johnston; Robert L. Coleman; Mark Munsell 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 118 KB 👁 2 views

## Abstract ## BACKGROUND: Dysregulation of phosphatase and tensin homolog (PTEN) and the gene that encodes the p110α catalytic subunit of phosphatidylinositol‐3‐kinase (PI3K), PIK3CA, are the most common mutations in endometrial carcinoma (EC). Loss of PTEN or activation of PIK3CA results in cons

Preliminary characterization of oral les

Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients

✍ Stephen Sonis; Nathaniel Treister; Sant Chawla; George Demetri; Frank Haluska 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 176 KB

## Abstract ## BACKGROUND: Mammalian target of rapamycin (mTOR) inhibitors may have efficacy as an intervention for advanced malignancies. Oral ulceration (OU), reported as mucositis, has been a dose‐limiting toxicity for this new class of agents. An analysis of the appearance, course, and toxicit

359 Phase Ib and pharmacokinetic studies

359 Phase Ib and pharmacokinetic studies of Everolimus (RAD001), a novel oral mTOR-inhibitor, with paclitaxel in patients with advanced solid tumors

✍ M. Campone; V. Levy; V. Delecroix; E. Bourbouloux; D. Bootle; C. Tanaka; N. Shan 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 144 KB